Literature DB >> 32728224

Updated staging and patient outcomes in low-grade appendiceal mucinous neoplasms.

Samuel J Ballentine1,2, Jacquelyn Carr3, Eliahu Y Bekhor3, Umut Sarpel3, Alexandros D Polydorides4.   

Abstract

Low-grade appendiceal mucinous neoplasms (LAMNs) exhibit drastically different clinical course and prognosis depending on tumor stage, particularly as it relates to the extent and cellularity of peritoneal involvement. In this context, recent changes in staging guidelines have sought to clarify criteria for pT and pM categories. This study's aim was to identify clinicopathological features associated with patient outcomes, especially as they pertain to updated stage groups. We reviewed LAMNs from 192 patients (mean age: 56.9 years, 119 (62.0%) women). The tumors consisted of 66 (34.4%) pTisM0, 16 (8.3%) pT3M0, 16 (8.3%) pT4aM0, 27 (14.1%) pTxM1a, and 67 (34.9%) pTxM1b cases. In multivariate analysis, only gross perforation was significantly associated with higher TNM group stage (p = 0.001; OR 3.3, 95% CI: 1.7-6.4). Of 165 (85.9%) patients with clinical follow-up, 51 (30.9%) had disease progression (over a mean 33.7 months, range: 4.7-121.7), whereas over significantly longer follow-up (mean 48.7 months, range: 3.1-143.9; p = 0.004), 114 (69.1%) patients did not. In multivariate analysis, higher TNM stage was significantly associated with disease progression (p = 0.029; OR 18.3, 95% CI: 1.4-246.0). In Kaplan-Meier analysis, none of 74 patients with disease limited to the appendix (pM0), 6 of 27 (22.2%) cases with peritoneal involvement by acellular mucin only (pM1a), and 45 of 64 (70.3%) tumors with intraperitoneal deposits containing neoplastic cells (pM1b) showed disease progression (p < 0.001). These differences in progression-free survival among TNM groups persisted when limiting the analysis to patients who had undergone successful cytoreductive surgery (p = 0.050). Finally, in four patients (all with pM1b disease) death was attributed to disease progression whereas there was no disease-specific mortality in the pM0 and pM1a groups (p = 0.020). These data support the designation of LAMNs with acellular peritoneal mucin as having an intermediate prognosis between cases limited to the appendix and those with intraperitoneal deposits containing neoplastic epithelium.

Entities:  

Mesh:

Year:  2020        PMID: 32728224     DOI: 10.1038/s41379-020-0628-7

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  54 in total

1.  Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei".

Authors:  B M Ronnett; C M Zahn; R J Kurman; M E Kass; P H Sugarbaker; B M Shmookler
Journal:  Am J Surg Pathol       Date:  1995-12       Impact factor: 6.394

2.  Incidence and Survival of Appendiceal Mucinous Neoplasms: A SEER Analysis.

Authors:  Walid L Shaib; Michael Goodman; Zhengjia Chen; Sungjin Kim; Edith Brutcher; Tanios Bekaii-Saab; Bassel F El-Rayes
Journal:  Am J Clin Oncol       Date:  2017-12       Impact factor: 2.339

3.  Molecular genetic evidence supporting the clonality and appendiceal origin of Pseudomyxoma peritonei in women.

Authors:  C Szych; A Staebler; D C Connolly; R Wu; K R Cho; B M Ronnett
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

4.  Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review.

Authors:  Robert F Bradley; John H Stewart; Gregory B Russell; Edward A Levine; Kim R Geisinger
Journal:  Am J Surg Pathol       Date:  2006-05       Impact factor: 6.394

Review 5.  The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei.

Authors:  Norman J Carr; Frederic Bibeau; Robert F Bradley; Peggy Dartigues; Roger M Feakins; Kim R Geisinger; Xianyong Gui; Sylvie Isaac; Massimo Milione; Joseph Misdraji; Reetesh K Pai; Manuel Rodriguez-Justo; Leslie H Sobin; Marie-Louise F van Velthuysen; Rhonda K Yantiss
Journal:  Histopathology       Date:  2017-09-19       Impact factor: 5.087

6.  A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process.

Authors:  Norman J Carr; Thomas D Cecil; Faheez Mohamed; Leslie H Sobin; Paul H Sugarbaker; Santiago González-Moreno; Panos Taflampas; Sara Chapman; Brendan J Moran
Journal:  Am J Surg Pathol       Date:  2016-01       Impact factor: 6.394

7.  Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases.

Authors:  Joseph Misdraji; Rhonda K Yantiss; Fiona M Graeme-Cook; Ulysses J Balis; Robert H Young
Journal:  Am J Surg Pathol       Date:  2003-08       Impact factor: 6.394

8.  Appendiceal mucinous neoplasms: clinicopathologic study of 116 cases with analysis of factors predicting recurrence.

Authors:  Reetesh K Pai; Andrew H Beck; Jeffrey A Norton; Teri A Longacre
Journal:  Am J Surg Pathol       Date:  2009-10       Impact factor: 6.394

9.  Epithelial neoplasms of the appendix and colorectum: an analysis of cell proliferation, apoptosis, and expression of p53, CD44, bcl-2.

Authors:  Norman J Carr; Theresa S Emory; Leslie H Sobin
Journal:  Arch Pathol Lab Med       Date:  2002-07       Impact factor: 5.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.